News AZ boasts phase 3 win for self-administered gMG drug Alexion has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment for gMG.
News AstraZeneca reveals $50bn investment in US facilities Trump's pharma tariffs haven't appeared yet, but AstraZeneca has joined several of its peers with big investments in US manufacturing and R&D.
News Survival data back Tagrisso's role in first-line lung cancer Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?
News UK plan to lead life sciences gets mixed response The UK has unveiled its plan to revitalise the life sciences sector and become a global leader by 2030, but a pharma trade group says it falls short.
News AstraZeneca sifts for efficacy crumbs in amyloidosis trial AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup.
News MSD, AZ partner LaNova bought by Sino Biopharm for $951m LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.